CardiacAssist Inc. announced that it received a Class 3 CE-mark for its Protek Duo veno-venous cannula. The Protek Duo is licensed for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures. It has already been deployed at more than 50 hospitals in the United States since its initial launch in late 2014.

Scientific confirmation has just been published in the American Journal of Cardiovascular Disease that atherosclerosis, the underlying process of heart attacks and strokes, is generally not caused by high cholesterol blood levels. It is rather the result of a structural weakness of the blood vessel walls caused by chronic deficiency of ascorbate (vitamin C).

A new clinical trial is testing the feasibility and efficiency of a doctor in New York City remotely performing long-distance, tele-robotic ultrasound exams over the Internet on patients in Chicago.

Minneapolis Heart Institute Foundation, TMVR, Tendyne, FDA, first implant, U.S.

Minneapolis Heart Institute Foundation (MHIF) physicians are conducting a research study using the first transcatheter mitral valve replacement in the United States at Minneapolis Heart Institute at Abbott Northwestern Hospital.

Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for the 4 French, 1.25 Solid Diamondback 360 Peripheral Orbital Atherectomy System (OAS) for the treatment of peripheral artery disease (PAD). Specifically, the clearance covers the company’s 145-cm-long 1.25mm Diamondback 360 Solid Crown, 4 Fr sheath compatible and the Modified 1.25mm Diamondback 360 Micro Crown, 4 Fr sheath compatible.

Dave Fornell, Editor DAIC

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now